Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sab Biotherapeutics Inc
(NQ:
SABS
)
2.570
-0.100 (-3.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sab Biotherapeutics Inc
< Previous
1
2
3
4
5
6
Next >
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
April 13, 2023
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...
Via
Benzinga
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
April 04, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides Company Update for Full Year 2022
March 31, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
March 29, 2023
On Wednesday, 81 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 27, 2023
On Monday, 89 stocks made new 52-week lows.
Via
Benzinga
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
January 19, 2023
Conference to take place Feb. 6-9 in New York
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
March 24, 2023
On Friday, 469 companies hit new 52-week lows.
Via
Benzinga
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
January 18, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Receives Additional $8.2M In Closeout Of COVID-19 DoD Contract
January 18, 2023
SAB Biotherapeutics (NASDAQ: SABS) has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 11, 2023
Via
Benzinga
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
January 10, 2023
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study
January 10, 2023
SAB Biotherapeutics (NASDAQ: SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D)...
Via
Benzinga
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
January 09, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
January 05, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
December 29, 2022
On Thursday, 116 companies set new 52-week lows.
Via
Benzinga
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
December 15, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
December 07, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
November 29, 2022
Via
Benzinga
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
November 21, 2022
Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
November 15, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023
November 15, 2022
SAB Biotherapeutics' (NASDAQ: SABS) Q3 net loss reached $(7.1) million, equivalent to an EPS loss of $(0.16), as compared to a net loss of $(4.1) million a year ago. Cash and cash equivalents were $8.3...
Via
Benzinga
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
November 08, 2022
Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
November 03, 2022
SAB highlights data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19, showing broad efficacy against highly mutating viruses associated with respiratory disease
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Says Influenza, COVID-19 Candidates Showing Broad Efficacy Against Variants
November 03, 2022
SAB Biotherapeutics Inc (NASDAQ: SABS) presented an overview of its DiversitAb polyclonal platform at the 2022 Plasma Product Biotechnology Conference.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 01, 2022
Gainers
Via
Benzinga
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
October 27, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
October 10, 2022
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 05, 2022
Gainers
Via
Benzinga
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday
October 10, 2022
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday.
Via
Benzinga
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
October 06, 2022
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.